Annanim News
Now
CybersecurityMore stories: Apache Roller, F5 flaws, Rockwell and AGILOX, and quantum researchCybersecurityUkraine and the FBI arrest four suspects in a ransomware gang that collected more than $40 millionQuantum & precision measurementNIST shows the first complete quantum position verification: quantum physics confirms where a person isAutonomous vehiclesTesla tightens driver monitoring in its European driving system: hands on the wheel above 130 km/hCybersecurityPalo Alto Networks to acquire Applied Compute for $4.5 billion in stockModels & researchGoogle launches Gemini 4 Neon, a fast model for code, office work and agentsChinaChina Watch: Tencent raises its computing infrastructure spending sixfoldCybersecurityDecade-old NGINX flaw lets attackers run code on HTTP/2 servers without logging inRegulation & businessAnthropic prices its IPO at $83 a share, above the range, and starts trading on Nasdaq todayCybersecurityMore stories: cracking BitLocker PINs, Russian hackers and Nvidia's guaranteesSpace, satellites & commsVoyager 1 becomes the first human-made object one light-day from EarthCybersecurityIsrael's Vero Security raises $11 million to secure enterprise AI agentsAI agentsGoogle turns its Spark agent into Tasks inside Gemini and makes it free

Originally published:

Isomorphic Labs raises $5 billion to take drug candidates into clinical trials

The AI drug-discovery company spun out of Google's DeepMind in 2021 closed a $5 billion Series C. The money will fund further work on its drug-design engine and expansion into more types of medicine.

Isomorphic Labs raises $5 billion to take drug candidates into clinical trials
Image: TechCrunch (opens the source site in a new tab)

The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and all existing backers, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. It comes six months after a $2.1 billion Series B in May. The company did not disclose its new valuation; Bloomberg reported earlier this month that it was seeking to raise at a $50 billion valuation.

Isomorphic builds a drug-design engine that combines AI simulation models across different areas of chemistry and builds on AlphaFold, DeepMind's protein-structure prediction model. The company says its programmes have produced "positive preclinical results" in oncology and immunology, and it has deals with Eli Lilly, Novartis and Johnson & Johnson.

It is the first raise since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, moving into a chairman role at DeepMind. Hassabis and John Jumper won the Nobel Prize in Chemistry for AlphaFold. It is not yet known when the company's first drug will enter a clinical trial.

Sources

Topics

Install the app

In Safari: tap the Share button, then “Add to Home Screen”.